Inhibition of lung adenocarcinoma LA795 in mice by recombinant human endostatin.
OBJECTIVE: To evaluate the inhibitory effect of recombinant human endostatin on tumor growth and metastasis of adenocarcinoma LA795 in mice. METHODS: Recombinant human endostatin was purified rom endostadin-expressing pCX clones. LA795 cells were inoculated subcutaneously on the back of T739 mice, which were randomized into 2 groups. From the tenth day on, treatment group was given 20 mg/kg recombinant human endostatin subcutaneously daily for 14 consecutive days, and the control group received PBS in the same manner. The sizes of the subcutaneous tumors, lung weights, the number of metastases over the lung surface and the survival time of the mice were observed. RESULTS: The tumor sizes of the treatment group in creased slowly from (650+/-201) mm3 to (1 642+/-21) mm3 when compared with those of the control group which showed and increase from (623+/-248) mm3 to (9 194+/-952) mm3. The lung weight of the 2 groups was (190+/-25) mg and (324+/-43) mg respectively, and the number of lung sung surface metastases was 8+/-2 and 22+/-8 for each. The average survival time of the rats in the 2 groups was 48 d and 27 d, respectively. All parameters measured between the 2 groups showed significant differences (P<0.01). CONCLUSION: Recom binent human endostatin has strong inhibitory effect on both the growth of primary tumor and metastasis of lung adenocarcinoma LA795 cells, and prolongs the survival time of the tumor-bearing mice.